论文部分内容阅读
目的β2-微球蛋白对非霍奇金淋巴瘤患者的预后影响一直都存有争议,本文应用Meta分析的方法,综合定量评价β2-微球蛋白在非霍奇金淋巴瘤总体生存中的预后价值。方法依据一定纳入排除标准,通过Pubmed,Science Direct和OVID数据库检索1980～2010年的相关文献,提取或估算β2-微球蛋白正常组和升高组总体生存率的风险比并采用固定效应模型和随机效应模型对其合并,依据单/多因素进行亚组分析,采用敏感性分析,估计合并风险比的变化情况。同时,采用漏斗图和失安全系数估计发表偏倚。结果共纳入16篇符合要求的文献,累计病例2227例。异质性检验结果提示,各研究间具有异质性(χ2=85.68,P﹤0.001,I2=82%,df=15),在随机效应模型下,合并的风险比为2.67(95%CI1.86～3.83)。总体效应的检验具有统计学意义(Z=5.32,P﹤0.001)。结论升高的β2-微球蛋白水平是非霍奇金淋巴瘤预后生存的独立危险因素,这一发现有利于为非霍奇金淋巴瘤的治疗策略提供依据。
The purpose of β2-microglobulin prognosis in patients with non-Hodgkin’s lymphoma has been controversial, this paper the application of Meta analysis, a comprehensive quantitative evaluation of β2-microglobulin in the overall survival of non-Hodgkin’s lymphoma prognosis value. Methods According to the criteria of exclusion, the relevant literature from 1980 to 2010 was searched through Pubmed, Science Direct and OVID database to extract or estimate the risk ratio of the overall survival rate of β2-microglobulin normal group and elevated group. The fixed effect model and Random effects model of their merger, based on single / multi-factor analysis of subgroups, the use of sensitivity analysis to estimate changes in the combined risk ratio. At the same time, the publication bias was estimated using the funnel plot and the loss of safety factor. Results A total of 16 eligible documents were included, with a total of 2227 cases. Heterogeneity test results showed heterogeneity among studies (χ2 = 85.68, P <0.001, I2 = 82%, df = 15). The combined risk ratio was 2.67 (95% CI1) under the random-effects model. 86 ~ 3.83). The overall effect of the test was statistically significant (Z = 5.32, P <0.001). Conclusion The elevated β2-microglobulin level is an independent risk factor for prognosis of non-Hodgkin’s lymphoma. This finding is helpful for the treatment of non-Hodgkin’s lymphoma.